TheraRadar
← Back
Data updated: Mar 29, 2026

SHANGHAI HENGRUI

OncologyMetabolicDermatology
Generics

SHANGHAI HENGRUI is a generic drug manufacturer focused on Oncology, Metabolic, Dermatology.

2015
Since
2
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

SEVOFLURANE 2025-10-02
Labeling
DESFLURANE 2024-11-07
Labeling
SEVOFLURANE 2024-08-30
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 68%
0 drugs Phase 3: 2 Phase 2: 4 Phase 1: 22
Metabolic 11%
0 drugs Phase 3: 1 Phase 1: 2
Dermatology 7%
0 drugs Phase 2: 2
Neurology 7%
0 drugs Phase 2: 1 Phase 1: 2
Respiratory 7%
0 drugs Phase 2: 1 Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Eli Lilly big-pharma
Metabolic, Oncology, Neurology, Dermatology
ABBOTT big-pharma
Dermatology, Neurology, Metabolic, Respiratory
GSK big-pharma
Respiratory, Oncology, Neurology
Sanofi big-pharma
Metabolic, Oncology, Respiratory
Bayer big-pharma
Oncology, Dermatology, Metabolic